[EN] FUSED RING COMPOUNDS<br/>[FR] COMPOSÉS CYCLIQUES CONDENSÉS
申请人:GENENTECH INC
公开号:WO2020035031A1
公开(公告)日:2020-02-20
Provided are fused ring compounds of Formula (I), Formula (II), or Formula (III), as further detailed herein, which are used for the inhibition of Ras proteins, as well as compositions comprising these compounds and methods treatment by their administration.
SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF
申请人:UNIVERSITY OF TSUKUBA
公开号:US20180179151A1
公开(公告)日:2018-06-28
The present invention aims to provide a novel low-molecular-weight compound exhibiting an orexin receptor agonist activity and expected to be useful as a prophylactic or therapeutic agent for narcolepsy and the like. The present invention provides a compound represented by the formula (I):
wherein each symbol is as defined in the description, or a pharmaceutically acceptable acid addition salt thereof, which has an orexin receptor agonist activity, and an orexin receptor agonist containing the compound or a pharmaceutically acceptable acid addition salt thereof.
[EN] TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS<br/>[FR] COMPOSÉS TRIAZOLONE UTILISÉS COMME INHIBITEURS DE LA MPGES-1
申请人:GLENMARK PHARMACEUTICALS SA
公开号:WO2013186692A1
公开(公告)日:2013-12-19
The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.
Hair-coloring compositions comprise at least one self-coupling compound of Formula (1)
1
wherein R is a moiety selected from H, C
1-3
alkyl and C
1-3
hydroxyalkyl; R
1
is a C
1-3
alkylene radical and R
2
is selected from H and C
1-3
alkyl radicals.